2018 INVESTOR MATERIALS

2017 FORM 10-K

 


View the below digital version of our Form 10-K.

2018 PROXY STATEMENT

 

 

View the below digital version of our Proxy Statement.

You may request paper copies of the proxy materials by  email, online by phone by dialing 866-648-8133.

VOTING

YOUR VOTE IS IMPORTANT!

 

Vote online now or by phone by dialing

866-437-3716.

VOTE NOW

ANNUAL MEETING DETAILS

DATE:

 

 

TIME:

 

 

LOCATION:

May 16, 2018

 

 

10:00 AM Pacific Time

 

 

MannKind Corporation

30930 Russell Ranch Road, Suite 301

Westlake Village, CA 91362

ABOUT US

At MannKind Corporation (NASDAQ: MNKD), we focus on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension.

 

Our focus is patients, our passion is innovation.

 

Our Journey

Over twenty-five years ago, in February 1991, the company – now known as MannKind Corporation—was founded. Originally incorporated as Pharmaceutical Discovery Corporation (PDC) in Elmsford, New York, it developed its Technosphere® technology, a versatile drug delivery platform that allows the pulmonary administration of therapeutics currently requiring administration by injection, shortly after its formation.

 

In the mid-1990s, Alfred Mann – at the time, CEO of MiniMed Inc. – started working with PDC through a collaborative research effort and eventually became a significant shareholder.

 

In 2001, the company merged with two other companies owned by Alfred Mann (CTL Immunotherapies Corp. and Allecure Corp.) and the surviving company changed its name to MannKind Corporation. As a result of this merger, we relocated the corporate headquarters to Valencia, California while focusing the East coast operations – by this time, located in Danbury, Connecticut – on improving the Technosphere® technology and developing our innovative line of delivery devices.

 

In 2014, our first product Afrezza® (insulin human) inhalation powder, which we manufactured in our state-of-the art manufacturing facility in Danbury, Connecticut, was approved by the FDA and launched soon after. We are currently commercializing Afrezza, the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide.

 

Today, MannKind Corporation is headquartered in Westlake Village, California. The East coast operations reside in Danbury, Connecticut, and our field sales and field medical employees are dispersed across the United States to best serve our customers.

 

Learn more at www.mannkindcorp.com.

 

Powered by Donnelley Financial Solutions

Copyright © 2018 Mediant Communications Inc. All Rights Reserved.

 

INVESTOR MATERIALS

VOTING

ANNUAL MEETING DETAILS

May 16, 2018

 

 

10:00 AM Pacific Time

 

 

MannKind Corporation

30930 Russell Ranch Road, Suite 301

Westlake Village, CA 91362

ABOUT US